(NASDAQ: TARA) Protara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Protara Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TARA's revenue for 2025 to be $395,610,760, with the lowest TARA revenue forecast at $395,610,760, and the highest TARA revenue forecast at $395,610,760. On average, 2 Wall Street analysts forecast TARA's revenue for 2026 to be $983,538,659, with the lowest TARA revenue forecast at $178,825,211, and the highest TARA revenue forecast at $1,788,252,107.
In 2027, TARA is forecast to generate $2,124,521,253 in revenue, with the lowest revenue forecast at $443,861,552 and the highest revenue forecast at $3,805,180,954.